Etiopathogenesis of Nonalcoholic Steatohepatitis

 

 Buy Article Permissions and Reprints

ABSTRACT

The definable causes of nonalcoholic steatohepatitis (NASH) include jejunoileal bypass surgery (JIB), other causes of rapid and profound weight loss in obese subjects, total parenteral nutrition, drugs, industrial toxins, copper toxicity, and disorders characterized by extreme insulin resistance. However, the etiopathogenesis in most cases of NASH appears multifactorial. Obesity, type 2 diabetes, and hypertriglyceridemia are often associated with hepatic steatosis, and although this does not invariably lead to NASH, the fatty liver is vulnerable to hepatocellular injury initiated by reactive oxygen species (ROS). It is critical to understand not only the triggers for hepatitis (injury and inflammation) in NASH but also how this is perpetuated as chronic liver disease. The present focus is on whether the biochemical processes that generate oxidative stress lead to hepatocyte injury and secondary recruitment of inflammation or whether inflammation is the primary mediator of liver cell injury. Insulin resistance is a reproducible pathogenic factor in NASH. It favors accumulation of free fatty acids in the liver and predisposes to oxidative stress by stimulating microsomal lipid peroxidases and by the direct effects of high insulin levels in decreasing mitochondrial β-oxidation. CYP2E1 is normally suppressed by insulin but is invariably increased in the livers of patients with NASH. In rodent dietary models of steatohepatitis, CYP2E1 is the catalyst of microsomal lipid peroxidation, while in Cyp 2e1 nullizygous mice, CYP4A proteins are induced and function as alternative microsomal lipid peroxidases. Other studies implicate activation of peroxisome proliferator-activated receptor-α (PPARα) as leading to NASH; PPARα is a transcription factor that governs both microsomal (via CYP4A) and peroxisomal (β-oxidation) pathways of lipid oxidation and ultimately production of ROS. Increased lipid peroxidation is a crucial difference between the livers of rodents with experimental NASH and those of ob/ob genetically obese mice that have uncomplicated steatosis. Administration of endotoxin, through the release of tumor necrosis factor-α (TNF-α), provokes liver inflammation with hepatocyte injury in the steatotic liver. This may be particularly relevant in JIB and has been suggested as a pathogenic mechanism in primary NASH. It has been proposed that inheriting one or more copies of the hemochromatosis gene, C282Y, promotes fibrotic progression in NASH because of increased hepatic iron deposition, but recent studies have failed to confirm this. The relationship between the severity of hepatitis in NASH and progression to cirrhosis implies that products of the inflammatory infiltrate play a role in fibrogenesis. In summary, NASH can be regarded as the hepatic consequence of the metabolic syndrome (or syndrome X). Attention should now shift from steatosis, a generally benign process that is less evident in the advanced stages of cirrhosis, to the mechanisms for hepatocellular injury, inflammation, and hepatic fibrosis. In particular, the genetic, molecular, and cellular factors that ordain and moderate fibrosis in the context of steatohepatitis will be of greatest relevance to effective therapy and clinical outcome.

REFERENCES

• 1 Ludwig J, Viggiano T R, McGill D B. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.  Mayo Clin Proc . 1980;  55 434-438
  PubMedGoogle Scholar
• 2 Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients.  Am J Med . 1979;  67 811-816
  CrossrefPubMedGoogle Scholar
• 3 Batman P A, Scheuer P J. Diabetic hepatitis preceding the onset of glucose intolerance.  Histopathology . 1985;  9 237-243
  PubMedGoogle Scholar
• 4 Baldridge A D, Perez-Atayde A R, Graeme-Cook F. Idiopathic steatohepatitis in childhood: a multicentre retrospective study.  J Pediatr . 1995;  127 700
  PubMedGoogle Scholar
• 5 Teli M R, James O F, Burt A D. The natural history of nonalcoholic fatty liver.  Hepatology . 1995;  22 1714-1719
  CrossrefPubMedGoogle Scholar
• 6 Caldwell S H, Oelsner D H, Iezzoni J C. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying liver disease.  Hepatology . 1999;  29 664-669
  CrossrefPubMedGoogle Scholar
• 7 Brunt E M, Janney C G, Di Bisceglie M A. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.  Am J Gastroenterol . 1999;  94 2467-2474
  CrossrefPubMedGoogle Scholar
• 8 Koteish A, Diehl A M. Animal models of steatosis.  Semin Liver Dis . 2001;  21 89-104
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Pessayre S, Berson A, Fromenty B. Mitochondria in steatohepatitis.  Semin Liver Dis . 2001;  21 57-70
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Hocking M P, Davis G L, Franzini D A. Long-term consequences after jejunoileal bypass for morbid obesity.  Dig Dis Sci . 1998;  43 2493-2499
  PubMedGoogle Scholar
• 11 Peters R L, Gay T, Reynolds T B. Post-jejunoileal bypass hepatic disease. Its similarity to alcoholic liver disease.  Am J Clin Pathol . 1975;  63 318-331
  PubMedGoogle Scholar
• 12 Nazim M, Stamp G, Hodgson H J. Nonalcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth.  Hepatogastroenterology . 1989;  36 349-351
  PubMedGoogle Scholar
• 13 Yost R L, Duerson M C, Russell W L. Doxycycline in the prevention of hepatic dysfunction: an evaluation of its use following jejunoileal bypass in humans.  Arch Surg . 1979;  114 931-934
  PubMedGoogle Scholar
• 14 Tuma D J, Vanderhoof J A, Sorrell M F. Impaired hepatic drug metabolism after jejunoileal bypass in rats.  J Pharmacol Exp Ther . 1978;  206 167-171
  PubMedGoogle Scholar
• 15 Vanderhoof J A, Metz M J, Tuma D J. Effect of improved absorption on development of jejunoileal bypass- induced liver dysfunction in rats.  Dig Dis Sci . 1980;  25 581-586
  CrossrefPubMedGoogle Scholar
• 16 Vanderhoof J A, Tuma D J, Antonson D L. Etiology of jejunoileal bypass-induced liver dysfunction in rats.  Dig Dis Sci . 1981;  26 328-333
  CrossrefPubMedGoogle Scholar
• 17 Whelan G, Wood B. The metabolic consequences of jejunoileal bypass for obesity.  Aust N Z J Surg . 1980;  50 520-524
  PubMedGoogle Scholar
• 18 Baker H, Vanderhoof J A, Tuma D J. A jejunoileal bypass rat model for rapid study of the effects of vitamin malabsorption.  Int J Vitam Nutr Res . 1992;  62 43-46
  PubMedGoogle Scholar
• 19 Halsted C H. Obesity: effects on the liver and gastrointestinal system.  Curr Opin Gastroenterol . 1999;  15 154-158
  CrossrefPubMedGoogle Scholar
• 20 Luyckx F H, Lefebvre P J, Scheen A J. Nonalcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.  Diabetes Metab . 2000;  26 98-106
  PubMedGoogle Scholar
• 21 Peura D A, Stromeyer F W, Johnson L F. Liver injury with alcoholic hyaline after intestinal resection.  Gastroenterology . 1980;  79 128-130
  PubMedGoogle Scholar
• 22 Acosta D, Wenzel D G. Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells.  Atherosclerosis . 1974;  20 417-426
  PubMedGoogle Scholar
• 23 Hotamisligil G H, Spiegelman B M. Tumor necrosis factor-α. A key component of the obesity-diabetes link.  Diabetes . 1994;  43 1271-1278
  CrossrefPubMedGoogle Scholar
• 24 Yang S Q, Lin H Z, Lane M D. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis.  Proc Natl Acad Sci U S A . 1997;  94 2557-2562
  CrossrefPubMedGoogle Scholar
• 25 Chavin K D, Yang S, Lin H Z. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion.  J Biol Chem . 1999;  274 5692-5700
  PubMedGoogle Scholar
• 26 Song B J, Matsunaga T, Hardwick J P. Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat.  Mol Endocrinol . 1987;  1 542-547
  PubMedGoogle Scholar
• 27 Dong Z G, Hong J Y, Ma Q A. Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats.  Arch Biochem Biophys . 1988;  263 29-35
  CrossrefPubMedGoogle Scholar
• 28 Wigg A J, Roberts-Thomson I C, Dymock R B. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumour necrosis factor alpha in the pathogenesis of nonalcoholic steatohepatitis.  Gut . 2001;  48 206-211
  CrossrefPubMedGoogle Scholar
• 29 Hu Y, Ingelman-Sunberg M, Lindros K O. Induction mechanisms of cytochrome P450 2E1 in liver: interplay between ethanol treatment and starvation.  Biochem Pharmacol . 1995;  17 155-161
  PubMedGoogle Scholar
• 30 Quigley E M, Marsh M N, Shaffer J L. Hepatobiliary complications of total parenteral nutrition.  Gastroenterology . 1993;  104 286-301
  CrossrefPubMedGoogle Scholar
• 31 George D K, Goldwurm S, Macdonald G A. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.  Gastroenterology . 1998;  114 311-318
  CrossrefPubMedGoogle Scholar
• 32 Younossi Z M, Gramlich T, Bacon B R. Hepatic iron and nonalcoholic fatty liver disease.  Hepatology . 1999;  30 847-850
  CrossrefPubMedGoogle Scholar
• 33 Herion D W, Arioglu E, Doo E. Severe insulin resistance syndromes and nonalcoholic steatohepatitis. Proceedings of a Symposium on Nonalcoholic Steatohepatitis, National Institutes of Health, Bethesda, MD, 1998
  Google Scholar
• 34 Angulo P, Lindor K D. Treatment of nonalcoholic fatty liver: present and emerging therapies.  Semin Liver Dis . 2001;  21 81-88
  Article in Thieme ConnectPubMedGoogle Scholar
• 35 Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients.  Gastroenterology . 1990;  99 1408-1413
  PubMedGoogle Scholar
• 36 Cuellar R E, Tarter R, Hays A. The possible occurrence of `alcoholic hepatitis' in a patient with bulimia in the absence of diagnostic alcoholism.  Hepatology . 1987;  7 878-883
  PubMedGoogle Scholar
• 37 Capron J-P, Delamarre J, Dupas J-L. Fasting in obesity. Another cause of liver injury with alcoholic hyaline?.  Dig Dis Sci . 1982;  27 265-268
  CrossrefPubMedGoogle Scholar
• 38 Bowyer B A, Fleming C R, Ludwig J. Does long-term home parenteral nutrition in adult patients cause chronic liver disease?.  JPEN J Parenter Enteral Nutr . 1985;  9 11-17
  PubMedGoogle Scholar
• 39 Craig R M, Neumann T, Jeejeebhoy K N. Severe hepatocellular reaction resembling alcoholic hepatitis with cirrhosis after massive small bowel resection and prolonged total parenteral nutrition.  Gastroenterology . 1980;  79 131-137
  PubMedGoogle Scholar
• 40 Lewis J H, Mullick F, Ishak K G. Histopathologic analysis of suspected amiodarone hepatotoxicity.  Hum Pathol . 1990;  21 59-67
  CrossrefPubMedGoogle Scholar
• 41 Farrell G C. Drug-Induced Liver Disease. Edinburgh: Churchill Livingstone 1994
  Google Scholar
• 42 Pirovino M, Müller O, Zysset T. Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model.  Hepatology . 1988;  8 591-598
  CrossrefPubMedGoogle Scholar
• 43 Lewis J H, Ranard R C, Caruso A. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients.  Hepatology . 1989;  9 679-685
  CrossrefPubMedGoogle Scholar
• 44 Simon J B, Manley P N, Brien J F. Amiodarone hepatotoxicity simulating alcoholic liver disease.  N Engl J Med . 1984;  311 167-172
  PubMedGoogle Scholar
• 45 Pessayre D, Bichara M, Degott C. Perhexiline maleate-induced cirrhosis.  Gastroenterology . 1979;  76 170-177
  PubMedGoogle Scholar
• 46 Seki K, Minami Y, Nishikawa M. Nonalcoholic steatohepatitis induced by massive doses of synthetic estrogen.  Gastroenterol Jpn . 1983;  18 197-203
  PubMedGoogle Scholar
• 47 Cortez-Pinto H, Baptista A, Camilo M E. Tamoxifen-associated steatohepatitis-report of three cases.  J Hepatol . 1995;  23 95-97
  CrossrefPubMedGoogle Scholar
• 48 Ogawa Y, Murata Y, Nishioka A. Tamoxifen-induced fatty liver in patients with breast cancer.  Lancet . 1998;  351 725
  PubMedGoogle Scholar
• 49 Pratt D S, Knox T A, Erban J. Tamoxifen-induced steatohepatitis (Letter).  Ann Intern Med . 1995;  123 236
  PubMedGoogle Scholar
• 50 Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis (Letter).  Ann Intern Med . 1996;  124 855-856
  PubMedGoogle Scholar
• 51 Oien K A, Moffat D, Curry G W. Cirrhosis with steatohepatitis after adjuvant tamoxifen (Letter).  Lancet . 1999;  353 36-37
  CrossrefPubMedGoogle Scholar
• 52 Saibara T, Ogawa Y, Takahashi M. Tamoxifen-induced nonalcoholic steatohepatitis and bezafibrate (Abstract).  J Gastroenterol Hepatol . 2000;  15(Suppl) F96
  PubMedGoogle Scholar
• 53 Angulo P, Keach J C, Batts K P. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology . 1999;  30 1356-1362
  CrossrefPubMedGoogle Scholar
• 54 Beaugrand M, Denis J, Callard P. Tous les inhibiteurs calciques peuvent-ils entrainer des lésions d'hépatite alcoolique?.  Gastroenterol Clin Biol . 1987;  1 76
  PubMedGoogle Scholar
• 55 Babany G, Uzzan F, Larrey D. Alcoholic-like liver lesions induced by nifedipine.  J Hepatol . 1989;  9 252-255
  PubMedGoogle Scholar
• 56 Redlich C A, West A B, Fleming L. Clinical and pathologic characteristics associated with occupational exposure to dimethylformamide.  Gastroenterology . 1990;  99 748-757
  PubMedGoogle Scholar
• 57 Cotrim H P, Andrade Z A, Parana R. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers.  Liver . 1999;  19 299-304
  PubMedGoogle Scholar
• 58 Solis-Herruzo J A, Vidal J V, Colina F. Clinico-biochemical evolution and late hepatic lesions in the toxic oil syndrome.  Gastroenterology . 1987;  93 558-568
  PubMedGoogle Scholar
• 59 Belfiore F, Iannello S. Insulin resistance in obesity: metabolic mechanisms and measurement methods.  Mol Genet Metab . 1998;  65 121-128
  CrossrefPubMedGoogle Scholar
• 60 Powell E E, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy.  Gastroenterology . 1989;  97 1022-1024
  PubMedGoogle Scholar
• 61 Rashid M, Roberts E A. Nonalcoholic steatohepatitis in children.  J Pediatr Gastroenterol Nutr . 2000;  30 48-53
  CrossrefPubMedGoogle Scholar
• 62 Naschitz J E, Yeshurun D, Zuckerman E. Massive hepatic steatosis complicating adult celiac disease: report of a case and review of the literature.  Am J Gastroenterol . 1987;  82 1186-1189
  PubMedGoogle Scholar
• 63 Angulo P, Jorgensen R A, Lindor K D. Prevalence of serum antiendomysial antibodies in patients with nonalcoholic steatohepatitis.  Gastroenterology . 1999;  116 1184A
  PubMedGoogle Scholar
• 64 Partin J S, Partin J C, Schubert W K. Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis.  Gastroenterology . 1974;  67 107-118
  PubMedGoogle Scholar
• 65 Illingworth D R, Connor W E, Miller R G. Abetalipoproteinemia: report of 2 cases and review of therapy.  Arch Neurol . 1980;  37 659-662
  PubMedGoogle Scholar
• 66 Stromeyer F W, Ishak K G. Histology of the liver in Wilson's disease: a study of 34 cases.  Am J Clin Pathol . 1980;  73 12-24
  PubMedGoogle Scholar
• 67 Baker A, Gormally S, Saxena R. Copper-associated liver disease in childhood.  J Hepatol . 1995;  23 538-543
  CrossrefPubMedGoogle Scholar
• 68 Bavdekar A R, Bhave S A, Pradhan A M. Long term survival in Indian childhood cirrhosis treated with D-penicillamine.  Arch Dis Child . 1996;  74 32-35
  PubMedGoogle Scholar
• 69 Sheth S G, Gordon F D, Chopra S. Nonalcoholic steatohepatitis.  Ann Intern Med . 1997;  126 137-145
  PubMedGoogle Scholar
• 70 Ludwig J, McGill D B, Lindor K D. Review: nonalcoholic steatohepatitis.  J Gastroenterol Hepatol . 1997;  12 398-403
  CrossrefPubMedGoogle Scholar
• 71 James O FW, Day C P. Nonalcoholic steatohepatitis (NASH): a disease of emerging identity and importance.  J Hepatol . 1998;  29 495-501
  PubMedGoogle Scholar
• 72 Bacon B R, Farahvash M J, Janney C G. Nonalcoholic steatohepatitis: an expanded clinical entity.  Gastroenterology . 1994;  107 1103-1109
  PubMedGoogle Scholar
• 73 Lenaerts J, Verresen L, Van Steenbergen W. Fatty liver hepatitis and type 5 hyperlipoproteinemia in juvenile diabetes mellitus. Case report and review of the literature.  J Clin Gastroenterol . 1990;  12 93-97
  PubMedGoogle Scholar
• 74 Falchuk K R, Fiske S C, Haggitt R C. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus.  Gastroenterology . 1980;  78 535-541
  PubMedGoogle Scholar
• 75 Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. In: Popper H, Schaffner F (eds) Progress in Liver Disease, Vol III. New York: Grune & Stratton, 1970: 331
  Google Scholar
• 76 Mason A L, Lau J YN, Hoang N. Association of diabetes mellitus and chronic hepatitis C virus infection.  Hepatology . 1999;  29 328-333
  CrossrefPubMedGoogle Scholar
• 77 Petrides A S, Vogt C, Schulze-Berge D. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis.  Hepatology . 1994;  19 614-627
  PubMedGoogle Scholar
• 78 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.  Hepatology . 1990;  12 1106-1110
  CrossrefPubMedGoogle Scholar
• 79 Kakkar R, Kalra J, Mantha S V. Lipid peroxidation and activity of antioxidant enzymes in diabetic rats.  Mol Cell Biochem . 1995;  151 113-119
  CrossrefPubMedGoogle Scholar
• 80 Powell E E, Edwards-Smith C J, Hay J L. Host genetic factors influence disease progression in chronic hepatitis C.  Hepatology . 2000;  31 828-833
  PubMedGoogle Scholar
• 81 McClain C J, Barve S, Deaciuc I. Cytokines in alcoholic liver disease.  Semin Liver Dis . 1999;  19 205-219
  Article in Thieme ConnectPubMedGoogle Scholar
• 82 Hill D, Barve S, Joshi-Barve S. Increased monocyte nuclear factor-κB activation and tumor necrosis factor production on alcoholic hepatitis.  J Lab Clin Med . 2000;  135 387-395
  CrossrefPubMedGoogle Scholar
• 83 Farrell G C. Is bacterial ash the flash that ignites NASH (Editorial)?.  Gut . 2001;  48 148-149
  CrossrefPubMedGoogle Scholar
• 84 Andersen T, Gluud C. Liver morphology in morbid obesity: a literature study.  Int J Obes . 1984;  8 97-106
  PubMedGoogle Scholar
• 85 Marceau P, Biron S, Hould F-S. Liver pathology and the metabolic syndrome X in severe obesity.  J Clin Endocrinol Metab . 1999;  84 1513-1517
  CrossrefPubMedGoogle Scholar
• 86 Ratziu V, Giral P, Charlotte F. Liver fibrosis in overweight patients.  Gastroenterology . 2000;  118 1117-1123
  CrossrefPubMedGoogle Scholar
• 87 Naveau S, Giraud V, Borotto E. Excess weight risk factor for alcoholic liver disease.  Hepatology . 1997;  25 108-111
  CrossrefPubMedGoogle Scholar
• 88 Hourigan L F, MacDonald G A, Purdie D. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis.  Hepatology . 1999;  29 1215-1219
  CrossrefPubMedGoogle Scholar
• 89 Cortez-Pinto H, Camilo M E, Baptista A. Non-alcoholic fatty liver: another feature of the metabolic syndrome?.  Clin Nutr . 1999;  18 353-835
  PubMedGoogle Scholar
• 90 Fiatarone J R, Coverdale S A, Batey R G. Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis.  J Gastroenterol Hepatol . 1991;  6 585-590
  PubMedGoogle Scholar
• 91 Leclercq I A, Farrell G C, Field J. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis.  J Clin Invest . 2000;  105 1067-1075
  PubMedGoogle Scholar
• 92 Struben V MD, Hespenheide E E, Caldwell S H. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med .  2000;  108 9-13
  PubMedGoogle Scholar
• 93 Chitturi S, Fung C, Farrell G C. Prevalence of haemochromatosis gene mutations in nonalcoholic steatohepatitis (Abstract).  J Gastroenterol Hepatol (in press).
  PubMedGoogle Scholar
• 94 Khan M H, Farrell G C, Blyth K. Which patients with hepatitis C develop liver complications?.  Hepatology . 2000;  31 513-520
  CrossrefPubMedGoogle Scholar
• 95 Chitturi S, Fung C, Farrell G C. Clinical and biochemical predictors of advanced fibrosis in NASH (Abstract).  Hepatology . 2000;  32 535A
  PubMedGoogle Scholar
• 96 Houglum K, Ramm G A, Crawford D H. Excess iron induces hepatic oxidative stress and transforming growth factor-β1 in genetic hemochromatosis.  Hepatology . 1997;  26 605-610
  CrossrefPubMedGoogle Scholar
• 97 Bonkovsky H L, Banner B F, Lambrecht R W. Iron in liver diseases other than hemochromatosis.  Semin Liver Dis . 1996;  16 65-82
  PubMedGoogle Scholar
• 98 Deugnier Y, Turlin B, le Quilleuc D. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis.  Am J Surg Pathol . 1997;  21 669-675
  CrossrefPubMedGoogle Scholar
• 99 Bode C, Gast J, Zelder O. Alcohol-induced liver injury after jejunoileal bypass operation in rats.  J Hepatol . 1987;  5 75-84
  CrossrefPubMedGoogle Scholar
• 100 Whiting-O'Keefe Q E, Fyfe K H, Sack K D. Methotrexate and histologic hepatic abnormalities: a meta-analysis.  Am J Med . 1991;  90 711-716
  PubMedGoogle Scholar
• 101 Fong D G, Nehra V, Lindor K D. Metabolic and nutritional considerations in nonalcoholic fatty liver.  Hepatology . 2000;  32 3-10
  CrossrefPubMedGoogle Scholar
• 102 Hashimoto T, Fujita T, Usuda N. Peroxisomal and mitochondrial fatty acid β-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor α and peroxisomal fatty acyl-CoA oxidase.  J Biol Chem . 1999;  274 19228-19236
  CrossrefPubMedGoogle Scholar
• 103 Fan C-Y, Pan J, Usuda N. Steatohepatitis, spontaneous peroxisomal proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisomal proliferator-activated receptor α natural ligand metabolism.  J Biol Chem . 1998;  273 15639-15645
  CrossrefPubMedGoogle Scholar
• 104 Marchesini G, Brizi M, Morselli-Labate A M. Association of nonalcoholic fatty liver disease with insulin resistance.  Am J Med . 1999;  107 450-455
  Google Scholar
• 105 Guebre-Xabier M, Yang S Q, Lin H Z. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage.  Hepatology . 2000;  31 633-640
  CrossrefPubMedGoogle Scholar
• 106 McCullough A J, Bugianesi E, Marchesini G. Gender-dependent alterations in serum leptin in alcoholic cirrhosis.  Gastroenterology . 1998;  115 947-953
  PubMedGoogle Scholar
• 107 Shimizu H, Kakizaki S, Tsuchiya T. An increase of circulating leptin levels in patients with liver cirrhosis.  Int J Obes Relat Metab Disord . 1998;  22 1234-1238
  CrossrefPubMedGoogle Scholar
• 108 Weltman M D, Leclerq I, Farrell G C. Hepatocyte cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis.  Hepatology . 1998;  27 128-133
  CrossrefPubMedGoogle Scholar
• 109 Raucy J L, Lasker J M, Kraner J C. Induction of cytochrome P450IIE1 in the obese overfed rat.  Mol Pharmacol . 1991;  39 275-280
  PubMedGoogle Scholar
• 110 Ekström G, Ingelman-Sundberg M. Rat-liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450(P-450 IIE1).  Biochem Pharmacol . 1989;  38 1313-1319
  CrossrefPubMedGoogle Scholar
• 111 Nanji A A, Zhao S, Sadrzadeh S M. Marked enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats.  Alcohol Clin Exp Res . 1994;  18 1280-1285
  PubMedGoogle Scholar
• 112 Weltman M D, Farrell G C, Liddle C. Increased hepatocyte CYP 2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.  Gastroenterology . 1996;  111 1645-1653
  PubMedGoogle Scholar
• 113 Kirsch R, Shephard E, Kirsch R. The rat nutritional model of nonalcoholic steatohepatitis: strain and gender studies (Abstract).  J Gastroenterol Hepatol . 2000;  15(Suppl) F81
  PubMedGoogle Scholar
• 114 Leclercq I, Field J, Enriquez A. Constitutive and inducible expression of hepatic CYP2E1 and CYP4A in leptin-deficient ob/ob mice.  Biochem Biophys Res Commun . 2000;  268 337-344
  CrossrefPubMedGoogle Scholar
• 115 Kono H, Bradford B U, Yin M. CYP2E1 is not involved in early alcohol-induced liver injury.  Am J Physiol . 1999;  277 G1259-1267
  PubMedGoogle Scholar
• 116 Wan Y-J, Cai J, Li J. Regulation of peroxisome proliferator activated receptor α mediated pathways in alcohol fed cytochrome P450 deficient mice (Abstract).  J Gastroenterol Hepatol . 2000;  15(Suppl) F90
  CrossrefPubMedGoogle Scholar
• 117 Enriquez A, Leclercq I, Farrell G C. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice and fa/fa Zucker rats.  Biochem Biophys Res Commun . 1999;  255 300-306
  CrossrefPubMedGoogle Scholar
• 118 Zhang C, Walker L M, Hinson J A. Oxidant stress in rat liver after lipopolysaccharide administration: effect of inducible nitric-oxide synthase inhibition.  J Pharmacol Exp Ther . 2000;  293 968-972
  PubMedGoogle Scholar
• 119 Fernandez-Checa J C, Kaplowitz N, Garcia-Ruiz C. Mitochondrial glutathione: importance and transport.  Semin Liver Dis . 1998;  18 389-401
  Article in Thieme ConnectPubMedGoogle Scholar
• 120 Yang S Q, Zhu H, Li Y B. Mitochondrial adaptations to obesity-related oxidant stress.  Arch Biochem Biophys . 2000;  378 259-268
  CrossrefPubMedGoogle Scholar
• 121 Matteoni C A, Younossi Z M, Gramlich T. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology . 1999;  116 1413-1419
  CrossrefPubMedGoogle Scholar
• 122 Crespo J, Amado J A, Garcia-Unzueta M T. Leptin and TNF alpha levels in hepatitis C and its relationship with hepatic fibrosis (Abstract).  J Hepatol . 2000;  32(Suppl 2) 65
  PubMedGoogle Scholar
• 123 Merli M, Valeriano V, Masini A. Leptin in cirrhotic patients (Abstract).  J Hepatol . 2000;  32(Suppl 2) 213
  PubMedGoogle Scholar
• 124 Potter J J, Womack L, Mezey E. Transdifferentiation of rat hepatic stellate cells results in leptin expression.  Biochem Biophys Res Commun . 1998;  244 178-182
  CrossrefPubMedGoogle Scholar